Can CYP2D6 poor metabolizer (PM) status be ruled out by a single genotyping assay?

被引：0
|
作者：
Gaedigk, A
Bradford, LD
Leeder, JS
机构：
[1] Childrens Mercy Hosp, Sect Dev Pharmacol & Expt Therapeut, Kansas City, MO 64108 USA
[2] Morehouse Sch Med, Atlanta, GA 30310 USA
来源：
DRUG METABOLISM REVIEWS | 2002年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
303
引用
收藏
页码：152 / 152
页数：1
相关论文
共 50 条
  • [31] Association of poor metabolizer genotypes (CYP2D6 and NAT2) with Parkinson's disease
    Singh, M.
    Shah, P. P.
    Shukla, R.
    Khanna, V. K.
    Parmar, D.
    MOVEMENT DISORDERS, 2008, 23 (01) : S199 - S199
  • [32] A rare insertion of T-226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15
    Sachse, C
    Brockmoller, J
    Bauer, S
    Reum, T
    Roots, I
    PHARMACOGENETICS, 1996, 6 (03): : 269 - 272
  • [33] Experience with CYP2D6 genotyping in psychiatry
    Eliasson, E
    Ufer, M
    Bohman, L
    PHARMACOPSYCHIATRY, 2005, 38 (01) : 48 - 48
  • [34] CYP2D6: NEW GENOTYPING METHODS
    Classen, Jean-Francois
    Pepermans, Xavier
    Vaerman, Jean-Luc
    Linden, Raphael
    Wallem-acq, Pierre
    Haufroid, Vincent
    ACTA CLINICA BELGICA, 2012, 67 (01): : 64 - 64
  • [35] CYP2C19 and CYP2D6 Genotypes and Metabolizer Status Distribution in a Bulgarian Psychiatric Cohort
    Ivanov, Hristo Y.
    Grigorova, Denitsa
    Lauschke, Volker M.
    Velinov, Branimir
    Stoychev, Kaloyan
    Kyosovska, Gergana
    Shopov, Peter
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (07):
  • [36] Implementation of CYP2D6 genotyping in psychiatry
    Loovers, Harriet M.
    van der Weide, Jan
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (09) : 1065 - 1077
  • [37] CYP2D6 genotyping and codeine - Reply
    Voronov, Polina
    PEDIATRIC ANESTHESIA, 2008, 18 (03) : 275 - 276
  • [38] A Faster and More Sensitive Assay for CYP2D6 and CYP2C19 Genotyping
    Freeman, E.
    Keddache, M.
    Saldana, S.
    Prows, C.
    Vinks, A. A.
    Glauser, T.
    Zhang, K.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2009, 11 (06): : 625 - 625
  • [39] Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment
    Li, Jingmei
    Czene, Kamila
    Brauch, Hiltrud
    Schroth, Werner
    Saladores, Pilar
    Li, Yi
    Humphreys, Keith
    Hall, Per
    BREAST CANCER RESEARCH, 2013, 15 (05)
  • [40] Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia
    Inglis, Sally C.
    Herbert, Megan K.
    Davies, Benjamin J. L.
    Coller, Janet K.
    James, Heather M.
    Horowitz, John D.
    Morris, Raymond G.
    Milne, Robert W.
    Somogyi, Andrew A.
    Sallustio, Benedetta C.
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (05): : 305 - 312
12345